Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphoma.

The COO subtypes were assigned as follows: 308 patients (51%) with activated B-cell-like (ABC)-DLBCL, 196 (33%) with germinal center B-cell-like (GCB)-DLBCL, 32 (5%) with DZsig-pos DLBCL and 66 (11%) with unclassified (UNC). H-score of CD79B was the lowest in patients with ABC-DLBCL followed by GCB-DLBCL and DZsig-pos DLBCL in ascending order (Kruskal-Wallis test I P i <.00001; Figure A). B Introduction: b CD79B is a target of polatuzumab vedotin, an antibody-drug conjugate, which may improve the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL). [Extracted from the article]